A
Adverse event
Australian Commission on Safety and Quality in Healthcare
Australian Capital Territory
Adverse Events
Australian Group on Antimicrobial Resistance
Acute Kidney Injury
Acute Liver Injury
Alanine Transaminase Test
Australian Orthopaedic Association National Joint Replacement Registry
Adverse reaction
Australasian Society for Infectious Diseases Clinical Research Network
Aspartate Transferase Test
Antimicrobial Use and Resistance Surveillance System
Australian Regional Trial Steering Committee
Australian Trial Management Group
B
Blood Culture
C
C. difficile Associated Diarrhoea
Coordinating Principal Investigator
Clinical Quality Registries
Case Report Form
Collaborative or Cooperative Research Group
C-reactive Protein
Clinical Trial Approval
Clinical Trial Management System
Clinical Trial Notification
Clinical Trials Research Agreement
D
Discharge
Debridement, Antibiotics and Implant Retention
Duration of Antibiotic Treatment in Prosthetic Joint Infection trial
Desirability Of Outcome Ranking
Domain-Specific Appendix
Data Safety and Monitoring Committee
Domain-Specific Working Group
E
The European Bone and Joint Infection Society
Electronic Case Report Form
Early Oral Switch
European Quality of Life Questionnaire, 5 Dimensions, 5 Level version
Extended-spectrum β-lactamases
G
Gram Positive
Good Clinical Practice
Global Trial Steering Committee
H
High Dependency Unit
Health Economic(s)
Health Economics Working Group
Hospital in the home
Heart Rate
Human Research Ethics Committee
I
Incremental Cost-Effectiveness Ratios
International Conference and Harmonisation Good Clinical Practice
International Committee of Medical Journal Editors
Intensive Care Unit
Infectious Disease physician
Infectious Diseases Society of America
International Interest Group
Inverse Probability of Censoring Weights
Interquartile Range
Institutional Review Board
Intention-to-treat
Intravenous
K
Kidney Disease: Improving Global Outcomes
M
Medicine Australia
Markov Chain Monte Carlo
Memorandum of Understanding
Methicillin-Resistant Staphylococcus aureus
Methicillin-Susceptible Staphylococcus aureus
N
Nucleic Acid Amplification Test
National Health and Medical Research Council
National Mutual Acceptance
Net Monetary Benefits
New South Wales
Northern Territory
O
Oxford Hip Score
Oxford Knee Score
Outpatient Parenteral Antimicrobial Therapy
Odds Ratio
P
Polymerase Chain Reaction
Principle Investigator
Prosthetic Joint Infection
Patients in the platform are those who meet all core eligibility criteria and consent to inclusion in the platform. Occasional patients in the platform will not receive any randomised intervention (if they are not eligible for any available domain).
“Platform entry” is the timepoint when the patient has met core eligibility criteria, given informed consent for the platform, and been randomised
Oral Administration
Purchasing Power Parity
Patient-Reported Outcome Measures
The International Prospective Register of Systematic Reviews
Penicillin-Susceptible Staphylococcus aureus
Q
Quality-adjusted Life Year
Queensland
Quality of Life
R
Response Adaptive Randomisation
Randomised Controlled Trial
Patients in the registry include all those in the platform (as defined above) PLUS the “registry only” patients. Registry only patients are those who are not in the platform, but who have consented to being in the registry.
Randomised Embedded Multifactorial Adaptive Platform
Research Governance Office
RandOmised Arthroplasty infection worlDwide Multidomain Adaptive Platform trial
ROADMAP Statistical Subcommittee
Region-Specific Appendix
Region-Specific Working Group
ROADMAP Statistics Working Group
Regional Trial Steering Committee
ROADMAP Registry working group
S
South Australia
Staphylococcus aureus Bacteraemia
Serious Adverse Event
Statistical Analysis Appendix
Serious Adverse Reaction
Southeastern Border States
The 12-item Short Form Survey is a patient-reported general health questionnaire
Statistical Implementation Guide (current state of the analytic plan based on any previous platform adaptations)
Standard Operating Procedures
Site specific assessment
Significant Safety Issue
Suspected Unexpected Serious Adverse Reactions
T
Tasmania
Therapeutic Goods Administration
Trial Management Group
U
Upper Limit Normal
University of Newcastle
Urgent Safety Measure
V
Victoria
W
Western Australia
Willingness to Pay
X
Extensively Drug Resistant
